Product information and disease descriptionPlace of product in therapyDisease description
Natural history, survival, and mortality
15 evidence topics · 19 sources
Enroll-HD: prospective observational natural history study, annual visits, and periodic data releases
“Enroll-HD is now operating worldwide in 21 countries at 159 clinical sites across four continents” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Europe, North America, Latin America, and Australasia” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“and has recruited almost 25,000 participants” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Central to the clinical research platform is the Enroll-HD study (NCT01574053), a prospective longitudinal observational study that collects natural history data in HD gene-expansion carriers (HDGECs) and non-HDGEC controls.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The Enroll-HD platform has been designed with the benefit of experience gained from several foundational HD studies” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“REGISTRY, PREDICT-HD, COHORT, and TRACK-HD/Track On-HD (12–16).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At their annual study visit, each participant is required to complete a core battery of assessments; extended and optional assessments are completed at the discretion of the PI and participant, respectively (Table 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“PDSs are prepared from the Enroll-HD study database every 1–2 years and include a large majority of the collected variables.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
TRACK-HD: 12-month changes in premanifest and early Huntington's disease
“TRACK-HD is a prospective observational study of Huntington's disease (HD) that examines disease progression in premanifest individuals carrying the mutant HTT gene and those with early stage disease.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“We report 12-month longitudinal changes, building on baseline findings.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Whole-brain atrophy rates were 0·20% (95% CI 0·05-0·34; p=0·0071) per year higher in preHD participants and 0·60% (0·44-0·76; p<0·0001) in early HD patients, and caudate atrophy rates were 1·37% (0·99-1·75; p<0·0001) per year higher in preHD and 2·86% (2·34-3·39; p<0·0001) in early HD.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Relative to controls, decline in cognition and quantitative motor function was detectable in both pre- and early HD, as was deterioration in oculomotor function in early HD.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Rate of functional decline on Total Functional Capacity: cohort of 960 participants followed prospectively
“The annual rate of functional decline was measured using the Total Functional Capacity Scale (TFC) and the Independence Scale (IS) in 960 patients with definite HD followed prospectively for a mean of 18.3 months.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The TFC score declined at a rate of 0.72 units/year (standard error [SE] 0.04) and the IS score declined at a rate of 4.52 units/year (SE 0.23).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Enroll-HD progression model: trajectories of functional, motor, and cognitive decline
“We included 8,071 Enroll-HD participants (mean baseline age: 51.4 years, 51.5% female) to develop a natural history progression model using baseline characteristics as predictive covariates.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Our analysis revealed that TFC and TMS are best characterized by logistic-like trajectories while cognitive scores (SDMT and SWR) display an exponential-like decline (Figure 1, B and C).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These results highlight the temporal differences in the rate of progression captured by different clinical end points and emphasize that individuals who exhibit rapid progression according to one clinical score may not necessarily exhibit fast progression according to another.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
GENERATION HD1 placebo arm compared with Enroll-HD natural history on Total Functional Capacity
“We observed that for the functional score (TFC), the progression during the trial aligns with the natural history progression, showing no sign of a relevant placebo response (Figure 4A).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“It is important to note that our analysis revealed that a placebo response initially leads to an improvement after baseline, but after accounting for this initial improvement, the rate of progression between the GENERATION HD1 placebo arm and Enroll-HD cohorts remained consistent.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Age at onset and prodromal phase
Prodromal change detected before diagnosis: PREDICT-HD
“1078 individuals with a CAG expansion were included in this analysis. Participants were followed up for a mean of 5·1 years (SD 3·3, range 0·0-12·0). 225 (21%) of these participants received a motor diagnosis of Huntington's disease during the study.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Disease stages: Huntington's Disease Integrated Staging System
“The HD-ISS characterises individuals for research purposes from birth, starting at Stage 0 (ie, individuals with the Huntington's disease genetic mutation without any detectable pathological change) by using a genetic definition of Huntington's disease. Huntington's disease progression is then marked by measurable indicators of underlying pathophysiology (Stage 1), a detectable clinical phenotype (Stage 2), and then decline in function (Stage 3).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Progression in premanifest and early disease: TRACK-HD
Survival after onset and age at death
“For these fully ascertained subjects, the range, mean, SD, and median of duration values were 0–46, 15.4, 6.8, and 15 years, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We found that, as with clinical onset, HD age at death is determined by expanded CAG-repeat length and has no contribution from the normal CAG allele. Surprisingly, disease duration is independent of the mutation's length.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Mortality relative to the general population: UK cohort
“The KM survival curve (Figure 1) shows a median survival time of 12.4 years (95% CI 10.6–15.2). Median age at death in individuals with HD and controls was 71 (IQR 59–79) and 81 (IQR 73–86) years, respectively. Individuals with HD were at 4.5 times greater risk of death than controls (hazard ratio 4.51, 95% CI 3.36–6.06, p < 0.001) after multivariable adjustment of baseline covariates (Figure S1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Age at death and causes of death: Norwegian national registries
“Mean age at death for individuals with HD was found to be 63.9 years (NCDR) and 61.7 years (CRD), compared to a mean of 76.9 years in the general population (NCDR).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In 73.5% of individuals with HD, the underlying cause of death was HD, followed by cardiovascular diseases, cancer and respiratory diseases. The most common immediate cause of death was respiratory diseases (44.2%). Suicide was a more common cause of death in the population with HD (2.3%) compared to the general population (1.3%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Causes of death: aspiration pneumonia
“Two hundred twenty four charts of deceased HD patients were reviewed, of which 216 (111/104 male/female, one unknown) had records available, 147 listed a cause of death (Table 1), which was pneumonia in 81 (55%) cases.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The conclusion is that the majority (86.8%) of our HD patients where the cause of death could be identified died from aspiration pneumonia.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Suicide and suicidal ideation
“Incidence of suicidal ideation, suicide attempt, and suicide are higher among those with HD relative to the non-HD population.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At baseline, 169 (8.0%) mutation carriers endorsed suicidal ideation.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The 4-year cumulative incidence of suicidal ideation was 9.9%.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Juvenile Huntington's disease: progression and survival
“Disease progression of JHD is faster compared to AOHD and the disease duration is shorter, particularly in case of higher CAG repeat lengths.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Disease progression was more rapid in juvenile Huntington's disease (n=14) than in adult-onset Huntington's disease (n=52; generalised estimating equation model, p=0·0003). Of 121 deceased patients, median survival was shorter in the juvenile Huntington's disease (n=17) cohort than in adult-onset Huntington's disease (n=104) cohort (hazard ratio 2·18 [95% CI 1·08-4·40]; p=0·002).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote